Voyager Therapeutics (VYGR) Net Margin (2015 - 2026)

Voyager Therapeutics has disclosed Net Margin across 12 years of filings, most recently posting 1077.4% for Q1 2026.

• Net Margin for Q1 2026 came in at 1077.4%, down 60015.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 318.97% (down 19262.0% YoY), and the FY2025 annual result was 296.53%, down 21528.0% from the prior year.
• Net Margin came in at 1077.4% for Q1 2026 at Voyager Therapeutics, down from 178.39% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 1524.26% in Q4 2022 to a low of 3239.97% in Q1 2022.
• The 5-year median for Net Margin is 208.15% (2025), against an average of 499.08%.
• Across the five-year window, Net Margin sank 284665 bps in 2022 and jumped 332240 bps in 2023, its largest moves.
• Voyager Therapeutics' Net Margin stood at 1524.26% in 2022, then slumped by 96 bps to 62.59% in 2023, then sank by 975 bps to 547.33% in 2024, then surged by 67 bps to 178.39% in 2025, then sank by 504 bps to 1077.4% in 2026.
• The last three Net Margin figures came in at 1077.4% (Q1 2026), 178.39% (Q4 2025), and 208.15% (Q3 2025), per Business Quant data.